Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Neurobiologie     Collection: Neuroimmunology     Display Documents



  history
ID: 524403.0, MPI für Neurobiologie / Neuroimmunology
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Authors:Kappos, L.; Radue, E. W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; Burtin, P.
Language:English
Date of Publication (YYYY-MM-DD):2010-02-04
Title of Journal:New England Journal of Medicine
Journal Abbrev.:N. Engl. J. Med.
Volume:362
Issue / Number:5
Start Page:387
End Page:401
Review Status:Peer-review
Audience:Not Specified
Abstract / Description:BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis. METHODS In our 24-month, double-blind, randomized study, we enrolled patients who had relapsing-remitting multiple sclerosis, were 18 to 55 years of age, had a score of 0 to 5.5 on the Expanded Disability Status Scale ( which ranges from 0 to 10, with higher scores indicating greater disability), and had had one or more relapses in the previous year or two or more in the previous 2 years. Patients received oral fingolimod at a dose of 0.5 mg or 1.25 mg daily or placebo. End points included the annualized relapse rate ( the primary end point) and the time to disability progression ( a secondary end point). RESULTS A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 1.25 mg significantly reduced the risk of disability progression over the 24-month period (hazard ratio, 0.70 and 0.68, respectively; P = 0.02 vs. placebo, for both comparisons). The cumulative probability of disability progression (confirmed after 3 months) was 17.7% with 0.5 mg of fingolimod, 16.6% with 1.25 mg of fingolimod, and 24.1% with placebo. Both fingolimod doses were superior to placebo with regard to MRI-related measures (number of new or enlarged lesions on T-2-weighted images, gadolinium-enhancing lesions, and brain-volume loss; P<0.001 for all comparisons at 24 months). Causes of study discontinuation and adverse events related to fingolimod included bradycardia and atrioventricular conduction block at the time of fingolimod initiation, macular edema, elevated liver-enzyme levels, and mild hypertension. CONCLUSIONS As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. These benefits will need to be weighed against possible long-term risks.
External Publication Status:published
Document Type:Article
Version Comment:Automatic journal name synchronization
Affiliations:MPI für Neurobiologie/Neuroimmunology (Wekerle)/Clinical Neuroimmunology (Hohlfeld)
External Affiliations:[Kappos, Ludwig] Univ Basel, Univ Hosp, Dept Neurol, CH-4031 Basel, Switzerland.; [Kappos, Ludwig] Univ Basel, Univ Hosp, Dept Biomed, CH-4031 Basel, Switzerland.; [Radue, Ernst-Wilhelm] Univ Basel, Univ Hosp, Med Image Anal Ctr, CH-4031 Basel, Switzerland.; [Agoropoulou, Catherine; Leyk, Malgorzata; Zhang-Auberson, Lixin; Burtin, Pascale] Novartis Pharmaceut, Basel, Switzerland.; [Polman, Chris] Free Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.; [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada.; [Calabresi, Peter] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.; [Selmaj, Krzysztof] Med Univ Lodz, Lodz, Poland.
Identifiers:ISI:000274193300005 [ID No:1]
ISSN:0028-4793 [ID No:2]
Full Text:
You have privileges to view the following file(s):
nejmoa0909494[1].pdf  [352,00 Kb] [Comment:free article]  
 
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.